RecruitingPhase 4NCT06379724

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management

Sponsor

University of Kansas Medical Center

Enrollment

62 participants

Start Date

Jul 11, 2024

Study Type

INTERVENTIONAL

Conditions

Burns Skin Graft Complications

Summary

Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Thrombin JMI, a drug called Tranexamic acid, and others for people with burns and skin graft complications. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTranexamic acid

100mg/mL 10mL vials x2 of injectable tranexamic acid will be filled into a 20 milliliter syringe with a spray tip.

DRUGThrombin JMI

The wound base is then sprayed with a film of Thrombin-JMI

PROCEDUREskin graft

Skin is taken from uninjured part of the participant's body and used to surgically cover a wound or injured area with skin that contains the epidermis and a portion of the dermis.